Evaluation of Andes virus vaccine-derived human antibody for protection in Syrian hamsters: a passive transfer study using phase 1 trial sera
Summary Background Andes virus (ANDV) causes severe hantavirus pulmonary syndrome and is uniquely capable of person-to-person transmission, with no licenced vaccines or therapeutics available. A Phase 1 trial (NCT03682107) demonstrated that an ANDV DNA vaccine targeting Gn/Gc envelope proteins elicits neutralising anti...